The Programme for the Integral, Transversal and Multidisciplinary Management of Aortic Valve Stenosis (MITMEVA) has already ensured that 15 patients1
Cardiology, cardiac surgery, orthopaedic surgery and traumatology, gastroenterology, endocrinology and nutrition, neurology and medical oncology are1
A team of physicians and researchers from UPF and from the hospitals Santa Creu i Sant Pau and Clínic de Barcelona, shows that the use of this innova1
A study coordinated by researchers at BCNatal-IDIBAPS, and published by the journal JAMA Cardiology, shows that people born with a low birth weight p1
This innovative vascular device represents a substantial improvement in the treatment of the obstructive disease and arterial aneurysms.
Dr. Bàrbara Vidal, cardiologist specialising in cardiac imaging and valvular heart disease The team from the Hospital Clínic Cardiovascular Institu1
It is the first platform specifically designed for this type of patient. It offers holistic patient follow-up, including physical training1
Hospital Clínic participated in a study which shows that the implantation of pacemakers and defibrillators has dropped by more than 50% during th1
Aortic valve stenosis (AVS) is a degenerative disease that causes a narrowing of the heart’s aortic valve. This narrowing prevents the valve from ope1
Women with heart disease are less likely to receive surgical treatment than men, even though it is associated with greater benefits for women. Data f1
